1. FDA approves Sarepta’s DMD drug that it had previously rejected — Biogen chalks up another failure — The House passes the Lower Drug Costs Now Act, but it’s unlikely to become law — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

CRISPR/Cas9 – Market Players Snapshot ?

Discussion in 'Amgen IT' started by naresh, Feb 25, 2016 at 7:24 AM.

  1. naresh

    naresh new user

    Joined:
    Dec 8, 2015
    Messages:
    4
    Likes Received:
    0
    Despite the ongoing patent war, a lot of startups and industry heavyweights have jumped on to the CRISPR/Cas9 bandwagon, seeing its potential in creating cures for various diseases such as AIDS, Cancer, and many more.Read here!